6 REFERENCES

1 Heidenreich PA, McClellan M. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. Amer J Med. 2001; 110:165-174.

2 Smith S, Blair SN, Bonow RO., et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation. 2001; 104:1577-1579.

3 Beller GA, Presidential Address: Quality of cardiovascular care in the U.S. J Amer Coll Cardiol. 2001; 38:587-594.

4 Califf RM, DeLong ER, Ostbye T et al. Underuse of Aspirin in a referral population with documented coronary artery disease. Am J Cardiol. 2002; 89:653-661.

5 Cook N, Chae C, Mueller F, Mis-medication and under-utilization of aspirin in the prevention and treatment of cardiovascular disease. Med Gen Med, November 22, 1999. (www.medscape.com).

6 Ferraris VA, Ferraris SP, Lough FC, et al. Preoperative aspirin ingestion increases operative blood loss after coronary artery bypassing grafting. Ann Thorac Surg. 1988; 45(1) 71-4.

7 Sethi GK, Copeland JG, Goldman S, et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of veterans affairs cooperative study on antiplatelet therapy. J Am Coll Cardiol. 1990; 15(1):21-2.

8 Bashein G, Nessly Ml, Rice Al, et al. Preoperative aspirin therapy and reoperation for bleeding after coronary artery bypass surgery. Arch Intern Med. 1991; 51(1):89-93.

9 Scher K, Unplanned reoperation for bleeding. Amer Surgeon. 1996; 62:52-55.

[10] Reich DL, Patel GC, Vela-Cantos, et al., Aspirin does not increase homologous blood requirements in elective coronary bypass surgery. Anesth Analg. 1994; 79(1):1-3.

[11] Vuylsteke A, Oduro A., Cardan E, Latimer RD. Effect of aspirin in coronary artery bypass grafting. Cardiothorac Vasc Anesth. 1997; 11(7):831-4.

[12] Neilipovitz D, Bryson G, Nichol G. The effect of perioperative aspirin therapy in peripheral vascular surgery: A decision analysis. Anesth Analg. 2001; 93:573-80.

[13] Dacey L, Munoz J, Johnson E, et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Cardiovasc Surg. 2000; 70:1986-90.

[14] Dacey L. Preoperative and immediate postoperative aspirin also reduces morbidity. Ann Thorac Surg. 2001; 72:1793-802.

[15] Mangano D, Layug E, Wallace A. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med. 1996; 335:1713-20.

[16] Poldermans D, Boersma E, Bax J, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med. 1999; 341:1789-94.

[17] Eagle K, Berger P, Calkins H, et al. AHA/ACC Guidelines Update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary. American Heart Association, Inc. 2002; 105:1257-1267.

[18] Spell NO. Stopping and restarting medications in the perioperative period. Med Clin N Amer. 2001; 85(5):1117-128.

[19] Jackson MR, Clagett GP. Antithrombotic therapy in peripheral occlusive disease. Chest. 2001; 119(suppl 1):283S-299S.

[20] Ardekian L, Gaspar R, Peled M, et al. Does low-dose aspirin therapy complicate oral surgical procedures? JADA. 2000; 131:331-335.

[21] The CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494-502.

[22] Gerschutz G, Bhatt D. The CURE trial: Using clopidogrel in acute coronary syndromes without ST-segment elevation. Cleveland Clinic Journal of Medicine. 2002; 69:377-384.

[23] Levy JH, Aspirin and bleeding after coronary artery bypass grafting. Anesth Analg. 1994; 79:1-3.

[24] Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med. 1996; 335(14):1001-1009.

[25] The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-57.

[26] Pitt B, Mancini GB, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995; 26:1133-9.

[27] Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995; 75:455-9.

[28] Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995; 91:2528-40.

[29] Shepherd J, Blauw G, Murphy M, et al. The design of a prospective study Pravastatin in the elderly at risk (PROSPER). Amer J Cardiol. 1999; 84:1192-1197.

[30] Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995; 76:69C-77C.

[31] Pfeffer MA, Sacks FM, Moye LA, et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. Am J Cardiol. 1995; 76:98C-106C.

[32] Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002; 105:1446-1452.

[33] American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 2000.